Aromatase inhibitors for breast cancer: Lessons from the laboratory

Nature Reviews Cancer

Volumn 3, Issue 11, 2003, Pages 821-831

  Johnston, Stephen R D ^a   Dowsett, Mitch ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; ESTROGEN; EXEMESTANE; FADROZOLE; FORMESTANE; FULVESTRANT; LETROZOLE; MEGESTROL ACETATE; TAMOXIFEN; TRIAZOLE DERIVATIVE; VOROZOLE;

BREAST CANCER; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG STRUCTURE; ENDOMETRIUM CANCER; FRACTURE; HORMONAL THERAPY; HORMONE DEFICIENCY; HORMONE SENSITIVITY; HOT FLUSH; HUMAN; ISCHEMIA; MUSCULOSKELETAL DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; THROMBOEMBOLISM; VAGINA BLEEDING; VAGINA DISCHARGE;

EID: 0242499440     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1211     Document Type: Review

References (98)

1. Early Breast Cancer Trialist Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351, 1451-1467 (1998).
2. Peto, R., Boreham, J., Clarke, M., Davies, C. & Beral, V. UK and USA breast cancer deaths down 25% in year 2000 at ages 29-60 years. Lancet 355, 1822 (2000).
3. Cuzick, J. et al. Overview of the main outcomes in breast cancer prevention trials. Lancet 361, 296-300 (2003).
4. McDonnell, D. P. & Connor, C. E., Wijayaratne, A., Chang, C. Y. & Norris, J. D. Definition of the molecular and cellular mechanisms underlying the tissue-selective agonist/antagonist activities of selective estrogen receptor modulators. Recent Prog. Horm. Res. 57, 295-316 (2002).
5. Girault, I. et al. Expression analysis of estrogen receptor α coregulators in breast carcinoma: evidence that NCOR1 expression is predictive of the response to tamoxifen. Clin. Cancer Res. 9, 1259-1266 (2003).
6. Ali, S. & Coombes, R. C. Endocrine-responsive breast cancer and strategies for combating resistance. Nature Rev. Cancer 2, 101-112 (2002).
7. Baum, M. et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359, 2131-2139 (2002). The first trial to report the relative benefits of a thirdgeneration aromatase inhibitor and tamoxifen as adjuvant therapy and to report that anastrozole was superior to tamoxifen.
8. Smith, I. E. & Dowsett, M. Aromatase inhibitors in breast cancer. N. Engl. J. Med. 348, 2431-2442 (2003). A recent comprehensive but concise review of the contemporary importance of aromatase inhibitors in breast cancer.
9. Kumar, V. et al. Functional domains of the human estrogen receptor. Cell 51, 941-951 (1987).
10. Reid, G. et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling. Mol. Cell 11, 695-707 (2003).
11. Osborne, C. K., Zhao, H. & Fuqua, S. A. W. Selective estrogen receptor modulators; structure, function, and clinical use. J. Clin. Oncol. 18, 3172-3186 (2000).
12. Levenson, A. S. & Jordan, V. C. Selective oestrogen receptor modulation: molecular pharmacology for the new millenium. Eur. J. Cancer 35, 1628-1639 (1999).
13. Brzozowski, A. M. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753-758 (1997).
14. Tora, L. et al. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59, 477-487 (1989).
15. Masamura, S., Santner, S. J., Heitjan, D. F. & Santen, R. J. Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J. Cells. Endocrinol. Metab. 80, 2918-2925 (1995). The first report that the acquired resistance of breast cancer cells in vitro to oestrogen deprivation is due to their acquisition of hypersensitivity to residual oestrogens.
16. Osborne, C. K., Hobbs, K. & Clark, G. M. Effect of estrogens and antiestrogens on growth of human breast cancer cells in athymic nude mice. Cancer Res. 45, 584-590 (1985).
17. Johnston, S. R. et al. Idoxifene antagonizes estradioldependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis. Cancer Res. 59, 3646-3651 (1999).
18. Detre, S. et al. Time-related effects of oestrogen withdrawal on proliferation and cell death-related events in MCF-7 xenografts. Int. J. Cancer 81, 309-313 (1999).
19. Brodie, A., Jelovac, D. & Long, B. J. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. Clin. Cancer Res. 9, 455S-459S (2003)
20. Simpson, E. R. & Dowsett, M. Aromatase and its inhibitors: significance for breast cancer therapy. Recent Prog. Horm. Res. 57, 317-338 (2002).
21. Miller, W. R. Aromatase and its inhibitors: new biology and clinical perspectives. Endocr. Relat. Cancer 6, 127-130 (1999).
22. Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J. Natl Cancer Inst. 94, 606-616 (2002). Clear demonstration that there is a direct association between plasma oestradiol and some other steroids with breast cancer risk in postmenopausal women.
23. Means, G. D. et al. Structural analysis of the gene encoding human aromatase cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J. Biol. Chem. 264, 19385-19391 (1989).
24. Kristensen, V. N. et al. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics 8, 43-48 (1998).
25. Haiman, C. A., Hankinson, S. E., Spiegelman, D., Brown, M. & Hunter, D. J. No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 11, 215-216 (2002).
26. Healey, C. S. et al. Polymorphisms in the human aromatase cytochrome P450 gene (CYP19) and breast cancer risk. Carcinogenesis 21, 189-193 (2000).
27. Masi, L. et al. Polymorphism of the aromatase gene in postmenopausal Italian women: distribution and correlation with bone mass and fracture risk. J. Clin. Endocrinol. Metab. 86, 2263-2269 (2001).
28. Dowsett, M., Dunning, A. M. & Healey, C. S. Association of Cyp19 (aromatase) and SHBG gene polymorphisms with plasma hormone levels in postmenopausal women: implications for breast cancer. Breast Cancer Res. Treat. 76, S154 (2003).
29. Pasqualini, J. R. et al. Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and postmenopausal breast cancer patients. J. Clin. Endocrinol. Metab. 81, 1460-1464 (1996).
30. Miller, W. R. & O'Neill, J. The importance of local synthesis of estrogen within the breast. Steroids 50, 537-548 (1987). Seminal data on the importance of oestrogen production in normal and malignant breast tissues.
31. Bulun, S. E., Sharda, G., Rink, J., Sharma, S. & Simpson, E. R. Distribution of aromatase P450 transcripts and adipose fibroblasts in the human breast. J. Clin. Endocrinol. Metab. 81, 1273-1277 (1996).
32. Harada, N., Utsumi, T. & Takagi, Y. Tissue-specific expression of the human aromatase cytochrome P-450 gene by alternative use of multiple exons 1 and promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc. Natl Acad. Sci. USA 90, 11312-11316 (1993).
33. Schrey, M. P. & Patel, K. V. Prostaglandin E2 production and metabolism in human breast cancer cells and breast fibroblasts. Regulation by inflammatory mediators. Br. J. Cancer 72, 1412-1419 (1995).
34. Coombes, R. C., Hughes, S.W. & Dowsett, M. 4-hydroxyandrostenedione: a new treatment for postmenopausal patients with breast cancer. Eur. J. Cancer 28A, 1941-1945 (1992).
35. Lonning, P. E. Pharmacology and clinical experience with exemestane. Expert Opin. Investig. Drugs 9, 1897-1905 (2000).
36. Kao, Y. C., Cam, L. L., Laughton, C. A., Zhou, D. & Chen, S. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. Cancer Res. 56, 3451-3460 (1996).
37. Dowsett, M. Theoretical considerations for the ideal aromatase inhibitor. Breast Cancer Res. Treat. 49, S39-S44 (1998).
38. Geisler, J., Haynes, B., Anker, G., Dowsett, M. & Lonning, P. E. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, crossover study. J. Clin. Oncol. 20, 751-757 (2002). Demonstration of the near-complete aromatase inhibition and oestrogen suppression that is achieved by third-generation non-steroidal aromatase inhibitors.
39. Harper-Wynne, C. L. et al. Comparison of the systemic and intratumoral effects of tamoxifen and the aromatase inhibitor vorozole in postmenopausal patients with primary breast cancer. J. Clin. Oncol. 20, 1026-1035 (2002). Differences in the molecular effects of aromatase inhibitors and tamoxifen are clearly shown in this paper - the first randomized neoadjuvant endocrine study in breast cancer.
40. Sinha, S. et al. Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat. Breast Cancer Res. Treat. 48, 45-51 (1998).
41. Dowsett, M., Stein, R. C., Coombes, R. C. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. J. Steroid Biochem. Mol. Biol. 48, 155-159 (1992).
42. Buzdar, A. et al. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopualsa women with advanced breast cancer: results of overview analysis of two phase III trials. J. Clin. Oncol. 14, 2000-2011 (1996).
43. Dombernowsky, P. et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomised trial showing a dose-effect and improved efficacy and tolerability compared with megestrol acetate. J. Clin. Oncol. 16, 453-461 (1998).
44. Kaufmann, M. et al. Exemestane is superior to megesterol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomised double-blind trial. J. Clin. Oncol 18, 1399-1411 (2000).
45. Smith, J. E., Harris, A. L. & Morgan, M. Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma. Cancer Res. 42, 3430-3433 (1982).
46. Falkson, C. I. & Falkson, H. C. A randomised study of GCS 16949A (fadrozole) versus tamoxifen in previoulsy untreated postmenopausal patients with metastatic breast cancer. Ann. Oncol. 7, 465-469 (1996).
47. Thurlimann, B. et al. First-line fadrozole HCL (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer. Ann. Oncol. 7, 471-479 (1996).
48. Bonneterre, J. et al. Anastrozole is superior to tamoxifen as first-line therapy in hormone-receptor positive advanced breast carcinoma. Cancer 92, 2247-2258 (2001).
49. Mouridsen, H. et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol 19, 2596-2606 (2001).
50. Heshmati, H. M. et al. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J. Bone Miner. Res. 17, 172-178 (2002).
51. Harper-Wynne, C. et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev. 11, 614-621 (2002).
52. The ATAC Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatement of postmenopausal women with earlystage breast cancer. Cancer (in the press).
53. Eiermann, W. et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomised double-blind multicentre study. Ann. Oncol. 12, 1527-1532 (2001).
54. Ellis, M. J. et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for erbB1 and/or erbB2 positive, estrogen receptor positive primary breast cancer: evidence from a phase III randomised trial. J. Clin. Oncol. 19, 3808-3816 (2001). Report of highly significant differences in the clinical efficacy of aromatase inhibitors and tamoxifen on ER-positive breast cancer that is also positive for ERBB2 or EGFR.
55. Lipton, A. et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J. Clin. Oncol. 21, 1967-1972 (2003).
56. Mouridsen, H. et al. Phase III study of tetrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. 21, 2101-2109 (2003).
57. Johnston, S. R. D. et al. Changes in estrogen receptor, progesterone receptor and pS2 expression in tamoxifenresistant human breast cancer. Cancer Res. 55, 3331-3338 (1995).
58. Johnston, S. R. D. et al. Comparison of estrogen receptor DNA-binding in untreated and acquired anti-estrogen resistant human breast tumors. Cancer Res. 57, 3723-3727 (1997).
59. Osborne, C. K., Coronado, E., Allred, D. C., Wiebe, V. & DeGregorio, M. Acquired tamoxifen resistance: correlation with reduced breast tumor levels of tamoxifen and isomerisation of trans-4-hydroxytamoxifen. J. Natl Cancer Inst. 83, 1477-1482 (1991).
60. Wolf, D. M. & Jordan, V. C. The estrogen receptor from a tamoxifen stimulated MCF-7 tumour variant contains a point mutation in the ligand binding domain. Breast Cancer Res. Treat. 31, 129-138 (1994).
61. Karnick, P. S., Kulkarni, S., Liu, X.-P., Budd, G. T. & Bukowski, R. M. Estrogen receptor mutations in tamoxifen-resistant breast cancer. Cancer Res. 54, 349-353 (1994).
62. Andersen, T. I. et al. Screening for estrogen receptor gene mutations in breast and ovarian cancer patients. Hum. Mutat. 9, 531-536 (1997).
63. Dowsett, M., Daffada, A., Chan, C. M. & Johnston, S. R. Oestrogen receptor mutants and variants in breast cancer. Eur. J. Cancer 33, 1177-1183 (1997).
64. Fuqua, S. A. W. et al. A hypersensitive estrogen receptor α mutation in premalignant breast lesions. Cancer Res. 60, 4026-4029 (2000).
65. Webb, P. et al. Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol. Endocrinol. 9, 443-456 (1995).
66. Dumont, J. A. et al. Progression of MCF-7 breast cancer cells to antiestrogen-resistant phenotype is accompanied by elevated levels of AP-1 DNA-binding activity. Cell Growth Differ. 7, 351-359 (1996).
67. Johnston, S. R. D. et al. Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin. Cancer Res. 5, 251-256 (1999).
68. Schiff, R. et al. Oxidative stress and AP-1 activity in tamoxifen-resistant breast tumors in vivo. J. Natl Cancer Inst. 92, 1926-1934 (2000).
69. Paech, K. et al. Differential ligand activation of estrogen receptors ERα and ERβ at AP-1 sites. Science 277, 1508-1510 (1997).
70. Kushner, P. J. et al. Estrogen receptor pathways to AP-1. J. Steroid Biochem. Mol. Biol. 74, 311-317 (2000).
71. Speirs, V., Malone, C., Walton, D. S., Kerin, M. J. & Atkin, S. L. Increased expression of estrogen receptor β mRNA in tamoxifen-resistant breast cancer patients. Cancer Res. 59, 5421-5424 (1999).
72. DeFriend, D. J. et al. Effects of 4-hydroxytamoxifen and a novel pureantioestrogen (ICI 182780) on the clonogenic growth of human breast cancer cells in vitro. Br. J. Cancer 70, 204-211 (1994). Compelling small translational study demonstrating the agonist activity of human breast cancer cells from patients with acquired tamoxifen resistance.
73. Howell, A. et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J. Clin. Oncol. 20, 3396-3403 (2002).
74. Osborne, C. K. et al. Double-blind, randomised trail comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J. Clin. Oncol. 20, 3386-3395 (2002).
75. McClelland, R. A. et al. Increased epidermal growth factor receptor signaling in MCF-7 breast cancer cells after longterm culture in the presence of the pure antiestrogen ICI 182,780 (Falsodex). Endocrinology 142, 2776-2788 (2001).
76. Knowlden, J. M. et al. Elevated levels of epidermal growth factor receptor/cerbB2 heterodiners mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144, 1032-1044 (2003).
77. Razandi, M., Pedram, A., Park, S. T. & Levin, E. R. Proximal events in signaling by plasma membrane estrogen receptors. J. Biol. Chem. 278, 2701-2712 (2003).
78. Levin, E. R. Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor. Mol. Endocrinol. 17, 309-317 (2003).
79. Stoica, G. E. et al. Estradiol rapidly activates Akt via the ErbB2 signaling pathway. Mol. Endocrinol. 17, 818-830 (2003).
80. Font de Mora, J. & Brown, M. AIB1 is a conduit for kinasemediated growth factor signaling to the estrogen receptor Mol. Cell. Biol. 20, 5041-5047 (2000).
81. Osborne, C. K. et al. Role of estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J. Natl Cancer Instit. 95, 353-361 (2003). First clinical evidence of the importance of the interaction between ER, ERBB2 and the steroid receptor co-activator AIB1.
82. Benz, C. C. et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER-2/neu. Breast Cancer Res. Treat. 24, 85-95 (1993).
83. Dowsett, M. et al. Molecular changes in tamoxifenrelapsed breast cancer; relationship between ER, HER2 and p38-MAP-kinase. Proc. Am. Soc. Clin. Oncol. 22, 3 (2003).
84. Massarweh, S. et al. Inhibition of epidermal growth factor/HER2 receptor signaling using ZD1839 (Iressa) restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressing breast tumors. Proc. Am. Soc. Clin. Oncol. 21, A33 (2002).
85. Kao, Y. C., Cam, L. L., Laughton, C. A., Zhou, D. & Chen, S. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. Cancer Res. 56, 3451-3460 (1996)
86. Sourdaine, P., Parker, M. G., Telford, J. & Miller, W. R. Analysis of the aromatase cytochrome P450 gene in human breast cancers. J. Mol. Endocrinol. 13, 331-337 (1994)
87. Santen, R. et al. Adaptive hypersensitivity to estradiol: potential mechanism for secondary hormonal responses in breast cancer patients. J. Steroid Biochem. Mol. Biol. 79, 115-125 (2001).
88. Chan, C. M. W., Martin, L.-A., Johnston, S. R. D., Ali, S. & Dowsett, M. Molecular changes associated with acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J. Steroid Biochem. Mol. Biol. 81, 333-341 (2002).
89. Martin, L.-A. et al. Enhnaced ER-α, ERB2 and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long-term estrogen deprivation. J. Biol. Chem. 278, 30458-30468.
90. Jeng, M.-H., Yue, W., Eischeid, A., Wang, J.-P. & Santen, R. J. Role of MAP kinase in the increased cell proliferation of long-term estrogen deprived human breast cancer cells. Breast Cancer Res. Treat. 62, 167-175 (2000).
91. Shim, W. S. et al. Estradiol hypersensitivity and mitogenactivated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinology 141, 396-405 (2000).
92. Stephen, R. L., Shaw, L. E., Larsen, C., Corcoran, D. & Darbre, P. D. Insulin-like growth factor receptor levels are regulated by cell density and by long-term estrogen deprivation in MCF-7 human breast cancer cells. J. Biol. Chem. 276, 40080-40086 (2001).
93. Campbell, R. A. et al. Phosphatidylinositol 3-Kinase/AKT-mediated activation of estrogen receptor α. J. Biol. Chem. 276, 9817-9824 (2001).
94. Haynes, B. P., Dowsett, M., Millar, W. R. & Bhatnager, A. S. The pharmacology of letrozole. J. Steroid Biochem. Mol. Biol. (in the press).
95. Buzdar, A. et. al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol. 19, 3357-3366 (2001).
96. Bergh, J. et al. Vorozole (Rivizor) versus aminoglutethimide (AG) in the treatment of postmenopausal breast cancer relapsing after tamoxifen. Proc. Am. Soc. Clin. Oncol. 16, 155A (1997).
97. Goss, P. E., Winer, E. P., Tannock, I. F. & Schwartz, L. H. Randomized phase III that comparing the new potent and selective third-generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients. North American Vorozole Study Group. J. Clin. Oncol. 17, 52-63 (1999).
98. Paridaens, R. et al. Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann. Oncol. 14, 1391-1398 (2003).